These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 14629482)

  • 1. Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients.
    Roussel-Robert V; Torchet MF; Legrand F; Rothschild C; Stieltjes N
    J Thromb Haemost; 2003 Nov; 1(11):2450-1. PubMed ID: 14629482
    [No Abstract]   [Full Text] [Related]  

  • 2. The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison.
    Hay CRM; Palmer BP; Chalmers EA; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Collins PW
    Haemophilia; 2015 Mar; 21(2):219-226. PubMed ID: 25382829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of inhibitors in previously untreated patients with hemophilia: a meta-analysis of literature studies.
    Di Minno MN; Marchesini E; Valdrè L
    Blood; 2015 Jun; 125(24):3819-21. PubMed ID: 26069336
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII.
    Parker ET; Craddock HN; Barrow RT; Lollar P
    J Thromb Haemost; 2004 Apr; 2(4):605-11. PubMed ID: 15102015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The management of hemophilia patients with inhibitors.
    Nilsson IM
    Transfus Med Rev; 1992 Oct; 6(4):285-93. PubMed ID: 1421831
    [No Abstract]   [Full Text] [Related]  

  • 6. Factor VIII brand and immunogenicity.
    Ragni MV
    Blood; 2014 Nov; 124(23):3337-8. PubMed ID: 25431473
    [No Abstract]   [Full Text] [Related]  

  • 7. More on: mild hemophilia A and inhibitor development.
    Koestenberger M; Leschnik B; Muntean W
    J Thromb Haemost; 2004 Apr; 2(4):676; author reply 677. PubMed ID: 15102028
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of agents that by-pass factor VIII inhibitors in patients with haemophilia.
    Roberts HR
    Vox Sang; 1999; 77 Suppl 1():38-41. PubMed ID: 10529686
    [No Abstract]   [Full Text] [Related]  

  • 9. Suggestions for the management of factor VIII inhibitors.
    Rubinger M; Rivard GE; Teitel J; Walker H;
    Haemophilia; 2000 Jul; 6 Suppl 1():52-9. PubMed ID: 10982269
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibitor development in prospective clinical trials with recombinant factor VIII preparations in previously untreated patients.
    Lusher JM
    Vox Sang; 1999; 77 Suppl 1():9. PubMed ID: 10529677
    [No Abstract]   [Full Text] [Related]  

  • 11. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC; Greenwood R; Escobar M; Frelinger JA
    Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor.
    Iioka F; Shimomura D; Nakamura F; Ohno H; Yada K; Nogami K; Shima M
    Haemophilia; 2014 Nov; 20(6):e402-4. PubMed ID: 25354772
    [No Abstract]   [Full Text] [Related]  

  • 13. Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?
    Hermans C; Astermark J; De Moerloose P
    J Thromb Haemost; 2012 Oct; 10(10):2194-6. PubMed ID: 22846047
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibitors in haemophilia: a primer.
    DiMichele DM
    Haemophilia; 2000 Jul; 6 Suppl 1():38-40. PubMed ID: 10982266
    [No Abstract]   [Full Text] [Related]  

  • 15. High-titer inhibitor development in hemophilia A: lack of product specificity.
    Hoots WK; Lusher J
    J Thromb Haemost; 2004 Feb; 2(2):358-9. PubMed ID: 14996014
    [No Abstract]   [Full Text] [Related]  

  • 16. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011.
    Collins PW; Palmer BP; Chalmers EA; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
    Blood; 2014 Nov; 124(23):3389-97. PubMed ID: 25339360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the treatment of hemorrhage in patients with hemophilia and associated inhibitors.
    Tarantino M; Aledort L
    Transfusion; 2001 Dec; 41(12):1628-9. PubMed ID: 11778084
    [No Abstract]   [Full Text] [Related]  

  • 18. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.
    Peyvandi F; Mannucci PM; Garagiola I; El-Beshlawy A; Elalfy M; Ramanan V; Eshghi P; Hanagavadi S; Varadarajan R; Karimi M; Manglani MV; Ross C; Young G; Seth T; Apte S; Nayak DM; Santagostino E; Mancuso ME; Sandoval Gonzalez AC; Mahlangu JN; Bonanad Boix S; Cerqueira M; Ewing NP; Male C; Owaidah T; Soto Arellano V; Kobrinsky NL; Majumdar S; Perez Garrido R; Sachdeva A; Simpson M; Thomas M; Zanon E; Antmen B; Kavakli K; Manco-Johnson MJ; Martinez M; Marzouka E; Mazzucconi MG; Neme D; Palomo Bravo A; Paredes Aguilera R; Prezotti A; Schmitt K; Wicklund BM; Zulfikar B; Rosendaal FR
    N Engl J Med; 2016 May; 374(21):2054-64. PubMed ID: 27223147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors, what is the risk of treatment intensity?
    Collins PW
    J Thromb Haemost; 2007 Jul; 5(7):1380-2. PubMed ID: 17445122
    [No Abstract]   [Full Text] [Related]  

  • 20. Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product.
    Rangarajan S; Jiménez-Yuste V; Santagostino E
    Haemophilia; 2014 Nov; 20(6):e414-7. PubMed ID: 25333452
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.